Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$120.28

-0.74 (-0.61%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

08:12
12/02/19
12/02
08:12
12/02/19
08:12

Seattle Genetics, Astellas Pharma announce ADC collaboration with Merck

Seattle Genetics (SGEN) and Astellas Pharma (ALPMY) announced a clinical collaboration agreement with Merck (MRK) to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate, or ADC, enfortumab vedotin and Merck's anti-PD-1 therapy, Keytruda, in patients with previously untreated metastatic urothelial cancer. Under the terms of the agreement, the three companies will conduct and fund a global, registrational phase 3 clinical trial to be led by Seattle Genetics. The trial will be designed to evaluate the efficacy of the combination of enfortumab vedotin and pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial cancer. The companies are working in consultation with regulatory authorities to finalize the trial design and currently plan to initiate the trial in the first half of 2020.

SGEN

Seattle Genetics

$120.28

-0.74 (-0.61%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

MRK

Merck

$87.10

-0.52 (-0.59%)

  • 04

    Dec

  • 07

    Dec

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

  • 15

    Mar

SGEN Seattle Genetics
$120.28

-0.74 (-0.61%)

10/22/19
OPCO
10/22/19
NO CHANGE
Target $110
OPCO
Outperform
Seattle Genetics price target raised to $110 from $92 at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan raised his price target for Seattle Genetics to $110 from $92 after tucatinib, the company's HER2+ targeting oral TKI, hit the primary endpoint of PFS improvement over control with a 46% reduction in the risk of disease progression or death. Tucatinib + trastuzumab + capecitabine also showed an improvement in OS with a 34% risk reduction and superior PFS in patients with brain metastases with a 52% risk reduction, he adds. The analyst views the early OS benefit as extremely positive as well as the brain metastasis outcome following his discussions with an expert at the MD Anderson brain metastasis clinic. Tuerkcan reiterates an Outperform rating on the shares.
10/22/19
RBCM
10/22/19
NO CHANGE
Target $109
RBCM
Outperform
Seattle Genetics price target raised to $109 from $80 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $109 after the "unexpectedly impressive" phase 3 data of its tucatinib drug in patients with HER2-positive breast cancer. The analyst is boosting his breadth and depth forecasts for tucatinib across indications, also raising his market penetration estimates to 75% from 45% and modeling peak risk adjusted sales of $531M and $171M in respective U.S. and EU5 markets. MacKay is keeping his Outperform rating on Seattle Genetics.
10/22/19
LEER
10/22/19
NO CHANGE
Target $120
LEER
Outperform
Seattle Genetics price target raised to $120 from $102 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Seattle Genetics to $120 from $102 following positive topline data from the pivotal HER2CLIMB trial for tucatinib. The analyst remains bullish on Seattle Genetics as a pipeline driven story, with positive momentum driven by enthusiasm for enfortumab vedotin in bladder cancer following strong data presented at ESMO, tucatinib HER2CLIMB success, which provides the company's first win in small molecules and a catalyst for a global footprint, and increasing confidence in the ADC + I/O synergy story, driving increased fundamental and strategic value for the ADC platform. He reiterates an Outperform rating on the shares.
10/29/19
PIPR
10/29/19
NO CHANGE
Target $120
PIPR
Overweight
Seattle Genetics price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target on Seattle Genetics to $120 after its "modest" beat on Adcetris revenue in Q3 along with an upwardly narrowed outlook for FY19. The analyst notes that the company has an "additional opportunity" driven by the potential launch for its Enfortumab vedotin, or EV, in 3rd-line UBC in 2020, along with other opportunities across the pipeline over the near term. Catanzaro also keeps his Overweight rating on Seattle Genetics.
ALPMY Astellas Pharma
$0.00

(0.00%)

09/24/19
JEFF
09/24/19
INITIATION
JEFF
Buy
Astellas Pharma initiated with a Buy at Jefferies
Jefferies analyst Stephen Barker started Astellas Pharma with a Buy rating and 2,000 yen price target.
MRK Merck
$87.10

-0.52 (-0.59%)

10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
10/30/19
MZHO
10/30/19
NO CHANGE
Target $100
MZHO
Buy
Merck price target raised to $100 from $97 at Mizuho
Mizuho analyst Mara Goldstein raised her price target for Merck to $100 from $97 saying the company delivered a "strong" Q3 earnings beat and raised fiscal 2019 sales and EPS guidance. The analyst continues to see opportunity for Keytruda to drive a profit transformation over the next several years and reiterates a Buy rating on the shares.
11/08/19
LEER
11/08/19
NO CHANGE
LEER
Outperform
Merck data a 'much needed positive' for Aduro Biotech, says SVB Leerink
SVB Leerink analyst Daina Graybosch noted that Merck (MRK) presented data in a late-breaking oral session at the SITC meeting on the dose escalation and confirmation phases of its trial of MK-5890, which is licensed from Aduro Biotech (ADRO). The "surprisingly positive" signal in dose escalation, while very early, should not have much stock impact for Merck, but for Aduro "this is some much needed positive news," according to Graybosch. She has an Outperform rating on Aduro shares.

TODAY'S FREE FLY STORIES

MRPLY

Mr Price Group

$0.00

(0.00%)

20:14
12/15/19
12/15
20:14
12/15/19
20:14
Upgrade
Mr Price Group rating change  »

Mr Price Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$341.67

-4.795 (-1.38%)

18:48
12/15/19
12/15
18:48
12/15/19
18:48
Periodicals
Boeing considering halting or cutting 737 MAX production, WSJ reports »

Boeing (BA) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEL

Xcel Energy

$62.27

0.91 (1.48%)

18:42
12/15/19
12/15
18:42
12/15/19
18:42
Initiation
Xcel Energy initiated at Goldman Sachs »

Xcel Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

$19.53

-0.6 (-2.98%)

18:38
12/15/19
12/15
18:38
12/15/19
18:38
Recommendations
Evoqua Water analyst commentary at Stifel »

Evoqua Water price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:33
12/15/19
12/15
18:33
12/15/19
18:33
Upgrade
Bluescope Steel rating change at JPMorgan »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

16:54
12/15/19
12/15
16:54
12/15/19
16:54
Upgrade
Bluescope Steel rating change at Macquarie »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$72.82

0.23 (0.32%)

16:36
12/15/19
12/15
16:36
12/15/19
16:36
Recommendations
Stifel adds Sage to Select List, says SAGE-217 will generate billions »

Stifel analyst Paul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$64.79

-1.39 (-2.10%)

16:10
12/15/19
12/15
16:10
12/15/19
16:10
Earnings
DuPont sees 2019 operating EBITDA at low end of guidance range »

DuPont reconfirms its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:07
12/15/19
12/15
16:07
12/15/19
16:07
Earnings
IFF affirms existing 2019 guidance for sales and earnings »

IFF is affirming its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:05
12/15/19
12/15
16:05
12/15/19
16:05
Hot Stocks
IFF, DuPont unit see revenue growth in mid-single digits over long term »

The company created by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$103.99

1.085 (1.05%)

, MAT

Mattel

$13.35

0.58 (4.54%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HAS

Hasbro

$103.99

1.085 (1.05%)

MAT

Mattel

$13.35

0.58 (4.54%)

FNKO

Funko

$15.16

0.23 (1.54%)

JAKK

JAKKS Pacific

$0.94

-0.0244 (-2.54%)

BBW

Build-A-Bear

$2.70

-0.05 (-1.82%)

MAS

Masco

$47.00

-0.44 (-0.93%)

FBHS

Fortune Brands

$65.09

-0.42 (-0.64%)

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
Hot Stocks
IFF to merge with DuPont's Nutrition & Biosciences unit via Reverse Morris Trust »

IFF (IFF) and DuPont (DD)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont to receive…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont holders will own…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:57
12/15/19
12/15
15:57
12/15/19
15:57
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors to…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILL

Bill.com

$38.59

3.09 (8.70%)

, EH

Ehang

$12.87

0.39 (3.13%)

15:25
12/15/19
12/15
15:25
12/15/19
15:25
On The Fly
Opening Day: XP finishes first week higher, Sprout Social lower »

This past week saw six…

BILL

Bill.com

$38.59

3.09 (8.70%)

EH

Ehang

$12.87

0.39 (3.13%)

HCCO

Healthcare Merger Corp.

$0.00

(0.00%)

OCFT

OneConnect

$10.08

(0.00%)

SPT

Sprout Social

$16.76

(0.00%)

XP

XP

$37.61

3.235 (9.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

15:09
12/15/19
12/15
15:09
12/15/19
15:09
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

, DG

Dollar General

$154.75

-0.885 (-0.57%)

14:31
12/15/19
12/15
14:31
12/15/19
14:31
Periodicals
Local governments want dollar stores selling fresh food, WSJ reports »

Local governments across…

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

DG

Dollar General

$154.75

-0.885 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELUXY

Electrolux

$0.00

(0.00%)

14:25
12/15/19
12/15
14:25
12/15/19
14:25
Hot Stocks
Electrolux sees $70M charge in Q4 from North America consolidation »

Electrolux provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$9.74

0.655 (7.21%)

, BP

BP

$36.95

-0.005 (-0.01%)

10:39
12/15/19
12/15
10:39
12/15/19
10:39
Recommendations
Barclays, BP, Amadeus IT Group, Anglo American, BT Group, Carlsberg, Demant, E.ON, Intertek, Novartis, Persimmon, Puma, RSA Insurance, Koninklijke Vopak, Hammerson, NMC Health, Reckitt Benckiser, Renault analyst commentary  »

Jefferies gives European…

BCS

Barclays

$9.74

0.655 (7.21%)

BP

BP

$36.95

-0.005 (-0.01%)

AMADY

Amadeus IT Group

$0.00

(0.00%)

NGLOY

Anglo American

$0.00

(0.00%)

BT

BT Group

$0.00

(0.00%)

CABGY

Carlsberg

$0.00

(0.00%)

WILYY

Demant

$0.00

(0.00%)

EONGY

E.ON

$0.00

(0.00%)

IKTSY

Intertek

$0.00

(0.00%)

NVS

Novartis

$93.00

-0.055 (-0.06%)

PSMMY

Persimmon

$0.00

(0.00%)

PUMSY

Puma

$0.00

(0.00%)

RSNAY

RSA Insurance

$0.00

(0.00%)

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

HMSNF

Hammerson

$0.00

(0.00%)

NMHLY

NMC Health

$0.00

(0.00%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 23

    Mar

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

05:55
12/15/19
12/15
05:55
12/15/19
05:55
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/15/19
12/15
04:55
12/15/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

, PYPL

PayPal

$107.68

2.01 (1.90%)

13:57
12/14/19
12/14
13:57
12/14/19
13:57
Periodicals
PNC clients having trouble connecting to PayPal's Venmo, WSJ reports »

Many of PNC…

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

PYPL

PayPal

$107.68

2.01 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 15

    Jan

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

, CMCSA

Comcast

$43.59

0.57 (1.33%)

07:44
12/14/19
12/14
07:44
12/14/19
07:44
Periodicals
Berkshire, Anthem among Barron's top 10 stock picks for 2020 »

Barron's has…

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

RDS.B

Royal Dutch Shell

$57.41

-0.19 (-0.33%)

RDS.A

Royal Dutch Shell

$57.44

-0.32 (-0.55%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

VIAC

ViacomCBS

$38.62

0.83 (2.20%)

ANTM

Anthem

$284.14

-0.405 (-0.14%)

DELL

Dell Technologies

$49.39

-0.11 (-0.22%)

GOOG

Alphabet

$1,348.07

-2.09 (-0.15%)

GOOGL

Alphabet Class A

$1,347.11

-1.4 (-0.10%)

UHAL

Amerco

$360.28

7.57 (2.15%)

UTX

United Technologies

$148.99

-0.5 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Feb

PCG

PG&E

$11.26

-0.49 (-4.17%)

07:38
12/14/19
12/14
07:38
12/14/19
07:38
Hot Stocks
California Governor says PG&E restructuring plan 'falls woefully short' »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.